Company
Xylocor
Gene therapy for advanced coronary artery disease
Also known as XyloCor Therapeutics, XyloCor Therapeutics, Inc.
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Legal name
- XyloCor Therapeutics, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
XyloCor Therapeutics is focused on improving the lives of patients through our commitment to advancing novel therapies for coronary artery disease.
Funding snapshot
- Total raised
- $21.4MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $4M2021-01-14
Funding rounds
- Round, 2021
- $4M2021-01-14, SEC form D sold, 5 investors
- Round, 2018
- $16.8M2018-10-04, SEC form D sold, 7 investors
- Round, 2018
- $200K2018-07-16, SEC form D sold, 1 investor
- Round, 2018
- $60K2018-03-05, SEC form D sold, 4 investors
- Round, 2017
- $100K2017-11-27, SEC form D sold, 1 investor
- Round, 2016
- $250K2016-11-10, SEC form D sold, 1 investor
Products
- Other
- XC001
- Web
- XC001
Loading relationship preview